Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer

oncodaily - Immune checkpoint blockade (ICB) benefits only a subset of patients with head and neck squamous cell carcinoma (HNSCC), and commonly used biomarkers (PD-L1, TMB) remain imperfect in this setting. This […]

AI Summary: Researchers reveal that an increased bacterial burden within head and neck tumors may undermine the efficacy of immune checkpoint blockade treatments. Detailed investigations indicate that intratumoral bacteria could be a pivotal factor in treatment resistance, opening new avenues for overcoming these challenges in managing advanced head and neck cancers.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Therapeutic HPV vaccine slows throat tumors in preclinical tests / 3 months

Gene‑editing trials explore one‑time fix for high cholesterol / 3 months

Bayer’s Asundexian Reduces Stroke Risk by 26% in Phase 3 Trial / 3 months

Eikon Therapeutics raises $381M IPO for cancer drug advancement / 3 months

Aktis Oncology IPO boosts radiopharmaceutical pipeline / 4 months

Giredestrant lowers recurrence risk in early-stage breast cancer / 5 months

Protego Bio Secures $130M for AL Amyloidosis Therapy Development / 5 months